Clinical trials: Major Depressive Disorder
Major Depression, Multiple Sclerosis
Escitalopram (Lexapro) for Depression MS or ALS
The purpose of this study is to see if escitalopram (Lexapro) improves symptoms of major depressive disorder in patients who have ALS or MS.
- Conditions
- Major Depression, Multiple Sclerosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT00965497
- Testing
- escitalopram
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of South Carolina
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436162
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
- Where
- 101 sites in United States, Belgium and 9 more
- Volunteers
- 1,105 people
- Sponsor
- Shire
Major Depressive Disorder (MDD)
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
The objectives of this exploratory trial are to evaluate the efficacy, safety, and subjects' subjective satisfaction when switching to adjunctive brexpiprazole in subjects with MDD who have responded inadequately to preceding…
- Trial name
- NCT02012218
- Testing
- ADT, Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 61 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients
The purpose of this study is to compare the efficacy and safety of duloxetine 60 mg once daily to placebo on depression in elderly patients (greater than or equal to 65 years of age).
- Trial name
- NCT00406848
- Testing
- duloxetine hydrochloride
- Where
- 33 sites in United States, France and 2 more
- Volunteers
- 370 people
- Sponsor
- Eli Lilly and Company
Depression, Mood Disorders
Rapid Antidepressant Effects of Ketamine in Major Depression
Depressive disorders may be severe, chronic and often life-threatening illnesses. Impairment in physical and social functioning resulting from depression can be just as severe as other chronic medical illnesses.
- Conditions
- Depression, Mood Disorders, Major Depresssion
- Trial name
- NCT00088699
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Depression
Enhancing the Effectiveness of Electroconvulsive Therapy in Severe Depression
Electroconvulsive therapy (ECT) is the most powerful antidepressant treatment available and is often life-saving. There are concerns, however, that standard bitemporal ECT (the most commonly used form of ECT worldwide) causes…
- Trial name
- EFFECT-Dep (NCT01907217)
- Testing
- ECT Mecta 5000M, Methohexitone, Suxamethonium
- Where
- Ireland
- Volunteers
- 138 people
- Sponsor
- St Patrick's Hospital, Ireland
Major Depression, End Stage Renal Disease
Bupropion for Depression in ESRD Patients on Hemodialysis
The proposed study will evaluate the response and remission rates for major depressive disorder (MDD) in end-stage renal disease (ESRD) patients undergoing maintenance hemodialysis (HD) treated with bupropion or fluoxetine for 12…
- Trial name
- NCT02238977
- Testing
- Fluoxetine, Bupropion
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Arkansas
Major Depressive Disorder (MDD)
Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression
This feasibility study investigates effects of EEG-based low frequency, low emission magnetic cortical stimulation in comparison to a sham treatment in subjects with moderate to severe depressive disorder.
- Trial name
- NCT01683019
- Testing
- NeoSync EEG Synchronization Therapy
- Where
- 2 sites in United States, China
- Volunteers
- 52 people
- Sponsor
- Wave Neuroscience
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
This a Phase 2a, multicenter, randomized, double-blind, placebo controlled 3 arm study to assess the safety and tolerability of multiple oral doses of REL-1017 25 mg and 50 mg as adjunctive therapy in the treatment of patients…
- Trial name
- NCT03051256
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- Relmada Therapeutics, Inc.
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Major Depressive Disorder
The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
- Trial name
- VLZ-MD-01 (NCT01473381)
- Testing
- Vilazodone, Citalopram
- Where
- 54 sites in United States
- Volunteers
- 1,162 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01838681
- Testing
- Brexpiprazole, ADT
- Where
- 107 sites in United States, Bulgaria and 14 more
- Volunteers
- 1,986 people
- Sponsor
- H. Lundbeck A/S
Depression
Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
This study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.
- Trial name
- NCT00200902
- Testing
- Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro), Interpersonal Clinical Interaction (ICI)
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of California, Los Angeles
Major Depressive Disorder
Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)
The objective of this study is to allow patients who have participated in the precursor study of BCI-024 in combination with BCI-049 versus placebo or BCI-024 alone (Protocol #CBM-IT-01) to receive 6 weeks of open-label treatment…
- Trial name
- NCT00731653
- Testing
- Combination Product: BCI-024 + BCI-049
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder
This is a study with an Open-Label (OL) phase followed by a randomized, Double-Blind (DB), placebo-controlled phase to assess efficacy and safety of SAGE-217 on relapse prevention in adults with major depressive disorder (MDD).
- Trial name
- NCT04007367
- Testing
- SAGE-217
- Where
- 46 sites in United States
- Volunteers
- 53 people
- Sponsor
- Biogen
Major Depressive Disorder
Pilot Study of Open-label Placebo to Treat Major Depressive Disorder
Placebo pills (pills with no active ingredients) have been shown in research studies to somehow produce self-healing processes. The purpose of this study is to determine whether people will be willing to enter an open-label…
- Trial name
- NCT01103271
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, Major Depression
Behavior During Experimentally Induced Pain
Numerous factors can influence the processing of pain message: the affective or emotional, the sensorial and the cognitive components.
- Trial name
- NCT01594528
- Testing
- pain tests
- Where
- France
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Esquirol
Major Depressive Disorder
A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy in patients with major depressive disorder.
- Trial name
- NCT02395978
- Testing
- PDC-1421 Capsule
- Where
- 5 sites in United States, Taiwan
- Volunteers
- 72 people
- Sponsor
- BioLite, Inc.
Major Depressive Disorder
A Novel Cognitive Remediation Intervention Targeting Poor Decision-making and Depression in Veterans at High Risk for Suicide: A Safe, Telehealth Approach During the COVID-19 Pandemic
Despite large-scale, nationwide efforts to better address suicidal behavior in Veterans at high risk, the development of interventions that target some of the key risk factors associated with suicide remains limited.
- Trial name
- CogRemVet (NCT04952532)
- Testing
- Neuropsychological Educational Approach to Cognitive Remediation (NEAR, termed Cognitive Remediation plus Bridging)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
The overarching purpose of this pilot study is to collect preliminary data regarding the variability of weight gain associated with lurasidone (Latuda©) treatment of antipsychotic naive children and adolescents in order to inform…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS
- Trial name
- NCT01731119
- Testing
- Latuda©
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of North Carolina, Chapel Hill
Major Depressive Disorder
A Study of the Effect of LY2216684 on Lorazepam
The purpose of this study is to determine how much lorazepam gets into the blood and how long it takes the body to get rid of it when given together with LY2216684.
- Trial name
- NCT01275144
- Testing
- LY2216684, Lorazepam
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company